- Home
- ADT vs HALO Comparison
ADT vs HALO Comparison
Compare ADT & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADT
- HALO
- Stock Information
- Founded
- ADT 1874
- HALO 1998
- Country
- ADT United States
- HALO United States
- Employees
- ADT N/A
- HALO N/A
- Industry
- ADT Diversified Commercial Services
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADT Consumer Discretionary
- HALO Health Care
- Exchange
- ADT Nasdaq
- HALO Nasdaq
- Market Cap
- ADT 7.0B
- HALO 7.6B
- IPO Year
- ADT 2018
- HALO N/A
- Fundamental
- Price
- ADT $8.60
- HALO $75.72
- Analyst Decision
- ADT Buy
- HALO Buy
- Analyst Count
- ADT 5
- HALO 8
- Target Price
- ADT $9.34
- HALO $70.25
- AVG Volume (30 Days)
- ADT 9.4M
- HALO 1.8M
- Earning Date
- ADT 10-23-2025
- HALO 10-30-2025
- Dividend Yield
- ADT 2.54%
- HALO N/A
- EPS Growth
- ADT N/A
- HALO 68.93
- EPS
- ADT 0.68
- HALO 4.37
- Revenue
- ADT $5,058,741,000.00
- HALO $1,178,672,000.00
- Revenue This Year
- ADT $6.26
- HALO $32.57
- Revenue Next Year
- ADT $4.28
- HALO $23.25
- P/E Ratio
- ADT $12.73
- HALO $17.40
- Revenue Growth
- ADT 6.58
- HALO 34.97
- 52 Week Low
- ADT $6.68
- HALO $42.01
- 52 Week High
- ADT $8.94
- HALO $77.60
- Technical
- Relative Strength Index (RSI)
- ADT 46.73
- HALO 70.70
- Support Level
- ADT $8.52
- HALO $75.19
- Resistance Level
- ADT $8.94
- HALO $76.61
- Average True Range (ATR)
- ADT 0.15
- HALO 1.68
- MACD
- ADT -0.02
- HALO -0.42
- Stochastic Oscillator
- ADT 14.84
- HALO 72.28
About ADT ADT Inc.
ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name. The company segments include Consumer and Small Business (CSB).
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.